Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
Giovanna Lalli, Jonathan M. Schott, John Hardy, Bart De Strooper
Abstract
the FDA approved aducanumab, the first new drug for Alzheimer's disease in almost 20 years-and notably, the first drug with a putative disease-modifying mechanism for the treatment of this devastating disorder, namely the removal of β-amyloid (or Aβ) plaques from the brain.
Topics & Concepts
DiseaseDrug developmentDrugMedicineAlzheimer's diseaseMechanism (biology)Drug discoveryAmyloid (mycology)PharmacologyBioinformaticsPathologyBiologyEpistemologyPhilosophyAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesNuclear Receptors and Signaling